CHMP adopts positive opinion on Zybrivo for non-squamous NSCLC
On 12 November 2026 the CHMP recommended granting a marketing authorization for Zybrivo, a sintilimab-based therapy, for first-line treatment of adult non-squamous non-small cell lung cancer. The recommendation follows a randomised, multicentre, double-blind, placebo-controlled study showing improved progression-free survival when sintilimab is combined with chemotherapy.
Primary source
EMA medicine page (CHMP opinion), November 13, 2026
Zybrivo (sintilimab): EMA CHMP opinion
Read the source: Zybrivo (sintilimab): EMA CHMP opinion ema.europa.eu
Machine-summarized from the source above; not independently reported. How we use automation